Procter & Gamble’s feminine care product sales grew 6% organically over the past three years and the firm anticipates stronger growth ahead in a global market for menstrual and incontinence care already at $34bn.
P&G's Feminine Care Sales Up As Incontinence, Menstrual Products Get Superiority Attention
Procter & Gamble CEO Jon Moeller and and feminine products chief Jennifer Davis outline firm's strategies and focus areas in sustainability and superiority in 2022. While more than half consumers are interested in natural or more sustainable products, few will settle for lesser product performance, Davis said. But they appear willing to pay a premium for products made with sustainable materials.
More from Strategy
• By
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
• By
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
More from Business
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”